Here is the title one h1 placeholder text

On January 27, marking the 10th anniversary of the company’s listing on the A-share market, we officially launched the global offering of H-shares, embarking on a brand-new journey to build an “A+A+H” capital platform!

The size of this H-share offering (stock abbreviation: Guoen Technology, stock code: 2768.HK) is 30 million shares. The initial price range for the offering is set between HK$34 and HK$42 per share. The book-building period runs from January 27 to January 30, 2026, and the company plans to list on the Hong Kong Stock Exchange on February 4.

The offering received an enthusiastic response from investors on its very first day. As of now, the public offering portion has exceeded HK$3.3 billion, with an oversubscription rate of nearly 30 times (Tiger Securities).

In this H-share offering, the company has received strong recognition and support from a number of well-established cornerstone investors, including Lihuan Investment Co., Ltd. (hereinafter referred to as “Lihuan”), SLD International Enterprises Limited (hereinafter referred to as “SLD”), Cheng’an International Co., Ltd. (hereinafter referred to as “Cheng’an International”), Sinolink Securities, First Seafront Fund Series SPC, Xinjia Wealth Securities Co., Ltd. (hereinafter referred to as “Xinjia Wealth”), Luminous Horizon Limited, and Fuguo Hong Kong (a wholly-owned subsidiary of Fuguo Fund). These prominent institutions collectively subscribed for approximately HK$320 million.

Among them, Liguan is backed by Qingdao Urban Investment Group—the largest state-owned investment platform in Qingdao—which boasts extensive investment experience in emerging industries. SLD International has close ties with Harbin Yuheng Pharmaceutical, a company with numerous mature products in the field of drug development. Luminous Horizon is wholly owned by Fosun Wealth International Holdings Limited. Investment firms such as Cheng’an International, Shenwan Hongyuan Securities, and Xinjia Wealth have frequently made moves in the capital markets; their investments in new-energy sectors—including automobiles—align closely with Guoen Shares’ core business of advanced materials. Moreover, Fuguo Hong Kong is a wholly-owned subsidiary of Fuguo Fund and is one of the first 10 fund management companies approved by regulatory authorities including the China Securities Regulatory Commission.

The dual recognition from industrial capital and financial investors underscores the company’s leading position in the fields of new chemical materials and greater healthcare.

Since its A-share listing in 2015, the company has continuously promoted technological innovation and industrial integration, wholeheartedly building a vertically integrated industrial platform. It has now established a complete new chemical materials industry chain—from green petrochemical materials to organically modified polymer materials and composite materials. The successful issuance of H-shares this time not only marks a crucial step in the company’s internationalization strategy but also represents an important move to respond to the nation’s call to “go global,” optimize global production capacity deployment, and deepen industrial synergy.

In the field of new chemical materials, the company has successfully established three major business pillars: green petrochemical new materials, organic polymer-modified materials, and organic polymer composite materials. It has built a vertically integrated industrial chain spanning “monomers—synthetic resins—organic polymer-modified/composite materials—end-use products,” serving leading enterprises in industries such as home appliances, automotive, and new energy. Currently, the company is China’s second-largest enterprise specializing in organic polymer-modified materials and organic polymer composite materials, and also China’s largest polystyrene manufacturer.

In the health industry, the company has achieved full-chain coverage—from gelatin raw materials to “collagen+” end products—by holding a controlling stake in Dongbao Bio (300239.SZ), a publicly listed company specializing in the collagen sector. Based on 2024 production volumes, the company is China’s second-largest producer of bone gelatin and the largest domestic-brand producer in this segment; it is also the second-largest domestic-brand manufacturer of hollow capsules.

The funds raised from this H-share offering by the company will be primarily used for the construction of a new production base in Thailand and for expanding production capacity in the Yangtze River Delta region, further strengthening our global supply chain layout and helping downstream customers jointly explore international markets.

Leveraging the international platform of Hong Kong’s capital market, the company will continue to enhance its corporate governance standards and optimize its financial structure, thereby creating long-term, sustainable value for shareholders, customers, and society.

We would like to extend our heartfelt gratitude to all our investors for your continued support and trust. Taking this H-share listing as an opportunity, Guoen Shares will accelerate its industrial upgrading and global expansion, and together with partners from all sectors, we will jointly build a high-quality future for our industry!